Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Lantheus made false statements and concealed information regarding its revenue outlook and growth potential, particularly related to the sales growth of its product Pylarify [2] - Allegations include that Lantheus misrepresented its understanding of market dynamics, including competition, pricing, seasonality, and macroeconomic factors [2] Group 2: Investor Information - Investors who suffered losses during the specified period have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth prospects, leading to a significant decline in stock price in August 2025 [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., seeks to recover damages for investors who purchased LifeMD securities during the class period from May 7, 2025, to August 5, 2025 [2][8]. Financial Misrepresentation - The lawsuit centers on LifeMD's financial guidance and public statements made after reporting strong Q1 results on May 6, 2025, where the company raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [6][7]. - The complaint alleges that this positive outlook was misleading as the company failed to disclose ongoing business challenges affecting revenue streams, including elevated customer acquisition costs and high patient refund rates [7][9]. Stock Price Impact - The issues came to light on August 5, 2025, when LifeMD announced its second-quarter results, missing revenue and earnings per share estimates, and subsequently slashed its full-year guidance. Following this announcement, LifeMD's stock price dropped by over 44% [7][9]. Investigation and Legal Action - Hagens Berman, a plaintiffs' rights firm, is investigating these claims on behalf of investors who suffered losses during the class period, focusing on when management became aware of the adverse information and whether their failure to disclose misled investors [10][11].

Accessibility StatementSkip Navigation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets 270k+JournalistsOpted In GET STARTED Also from this source LOS ANGELES, Oct. 1, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A ...

Core Viewpoint - A class action securities lawsuit has been filed against Lantheus Holdings, Inc. for alleged securities fraud affecting investors between February 26, 2025, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements and concealed information regarding the company's revenue outlook and growth potential, particularly related to Pylarify's sales growth and market dynamics [2]. - It is alleged that Lantheus did not accurately understand the pricing and competitive dynamics of Pylarify's market, contrary to the optimistic reports provided by the company [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Marex Group plc (“Marex” or the “Company”) (NASDAQ: MRX) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON MAREX GROUP PLC (MRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 5, 2025, NINGI Research published a report alleging, among ot ...

LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to KBR, Inc. ("KBR" or the "Company") (NYSE: KBR) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KBR, INC. (KBR), CLICK HERE BEFORE NOVEMBER 18, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. What Is The Lawsuit About? The complaint filed alleges that, between May 6, 2025 an ...

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 30, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against RCI Hospitality Holdings, Inc. ("RCI" or the "Company") (NASDAQ:Â RICK). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RCI HOSPITALITY HOLDINGS, INC. (RICK), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 20, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, Inc. and its executives, alleging that the company misrepresented its financial health and growth, leading to a significant decline in stock price in August 2025 [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, and seeks to recover damages for investors who incurred substantial losses during this timeframe [2]. Allegations of Misleading Information - The complaint indicates that on May 6, 2025, LifeMD reported strong first-quarter results and raised its full-year revenue and adjusted EBITDA guidance, claiming a "category-defining competitive moat" in virtual obesity care and strong performance from its RexMD brand [4]. - However, the lawsuit argues that this optimistic outlook was misleading as the company allegedly failed to disclose ongoing business challenges, including elevated customer acquisition costs and issues with patient refunds [5][10]. Stock Price Impact - Following the announcement of disappointing second-quarter results on August 5, 2025, which included missed revenue and earnings estimates and a reduction in full-year guidance, LifeMD's stock price fell by over 44% the next day [6][5]. Investigation by Hagens Berman - Hagens Berman, a national plaintiffs' rights firm, is investigating these claims on behalf of affected investors, focusing on whether LifeMD's management accurately represented the company's financial situation [7][8]. Key Issues Identified - The lawsuit highlights two main issues: rising customer acquisition costs in the RexMD segment and a higher-than-anticipated refund rate in the weight management business [10].

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Fly-E Group, Inc. (NASDAQ: FLYE)?Did you purchase your shares between July 15, 2025 and August 14, 2025, inclusive?Did you lose money in your investment in Fly-E Group, Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fly-E Group, Inc. (“Fly-E” or the “Company”) (NASDAQ: FLYE) investors of an upcoming deadline involving a securities f ...